<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03291106</url>
  </required_header>
  <id_info>
    <org_study_id>Lynch-PUMCH</org_study_id>
    <nct_id>NCT03291106</nct_id>
  </id_info>
  <brief_title>Study of Universal Screening for Lynch Syndrome in Chinese Patients of Endometrial Cancer</brief_title>
  <official_title>Cohort Study of Universal Screening for Lynch Syndrome in Chinese Patients of Endometrial Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lei Li</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In patients diagnosed as endometrial cancer by thorough pathologic examinations, Lynch
      syndromes are screened by (1)immunohistochemical staining (for MLH1, MSH2, MSH6 and PMS2),
      (2) tests of microsatellite instability and (3) clinical criteria (Amsterdam I or II criteria
      and Bethesda criteria). For patients with any suspicious discoveries of Lynch syndromes from
      aforementioned screening methods, a molecular diagnosis with next-generation sequencing for
      mismatch repair genes (MLH1, MSH2, MSH6, PMS2, and EPCAM) is given to confirm Lynch
      syndromes. For patients of Lynch syndromes and endometrial cancer, relatives of blood lineage
      are tested by Sanger method or qPCR to find out carriers of mutation genes of Lynch
      syndromes.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2017</start_date>
  <completion_date type="Anticipated">October 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Distribution of Lynch syndromes in endometrial cancer</measure>
    <time_frame>2 years</time_frame>
    <description>Proportions of patients carrying mismatch repair gene in endometrial cancer</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reliability of immunohistochemical staining for screening Lynch syndromes</measure>
    <time_frame>2 years</time_frame>
    <description>Sensitiviy and specitiviy of immunohistochemical staining for screening Lynch syndromes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reliability of microsatellite instability for screening Lynch syndromes</measure>
    <time_frame>2 years</time_frame>
    <description>Sensitiviy and specitiviy of microsatellite instability for screening Lynch syndromes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reliability of clinical criteria for screening Lynch syndromes</measure>
    <time_frame>2 years</time_frame>
    <description>Sensitiviy and specitiviy of clinical criteria for screening Lynch syndromes</description>
  </secondary_outcome>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>Colorectal Neoplasms, Hereditary Nonpolyposis</condition>
  <condition>Endometrial Neoplasms</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>immunohistochemical staining</intervention_name>
    <description>immunohistochemical staining for MLH1, MSH2, MSH6 and PMS2</description>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>tests of microsatellite instability</intervention_name>
    <description>microsatellite instability in tissues of endometrial cancer</description>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>clinical criteria of Lynch syndromes</intervention_name>
    <description>Amsterdam I or II criteria and Bethesda criteria</description>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>sequencing for mismatch repair genes</intervention_name>
    <description>next-generation sequencing, Sanger method or qPCR for mismatch repair genes (MLH1, MSH2, MSH6, PMS2, and EPCAM)</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patiens with definite diagnosis of endometrial cancer, including type I and type II
        endometrial cancer.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Survivals of endometrial cancer

        Exclusion Criteria:

          -  Metatatic malignacies to uterine

          -  Leiomyosarcoma of uterus
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lei Li, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking Union Medical College Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lei Li, MD</last_name>
    <phone>13911988831</phone>
    <phone_ext>+86</phone_ext>
    <email>lileigh@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Lei Li</name>
      <address>
        <city>Beijing</city>
        <state>China/Beiing</state>
        <zip>100000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lei L Li, MD</last_name>
      <phone>13911988831</phone>
      <phone_ext>+86</phone_ext>
      <email>lileigh@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 20, 2017</study_first_submitted>
  <study_first_submitted_qc>September 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 25, 2017</study_first_posted>
  <last_update_submitted>September 21, 2017</last_update_submitted>
  <last_update_submitted_qc>September 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Peking Union Medical College Hospital</investigator_affiliation>
    <investigator_full_name>Lei Li</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Endometrial Neoplasms</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Colorectal Neoplasms, Hereditary Nonpolyposis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Distributions of specific mutation genes of Lynch syndromes will be available for other researches by officially published papers.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

